{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T23:42:36Z","timestamp":1762040556268,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.humpath.2021.07.010","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T06:01:11Z","timestamp":1628143271000},"page":"51-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Clinicopathological features of and neoadjuvant therapy for human epidermal growth factor receptor 2-positive classic invasive lobular carcinoma"],"prefix":"10.1016","volume":"117","author":[{"given":"Xiao","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"QingQing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-8632","authenticated-orcid":false,"given":"Melissa K.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya W.","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-6058","authenticated-orcid":false,"given":"Bora","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysegul A.","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2021.07.010_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.seminoncol.2019.03.002","article-title":"Invasive lobular breast cancer: a review of pathogenesis, diagnosis, management, and future directions of early stage disease","volume":"46","author":"Thomas","year":"2019","journal-title":"Semin Oncol"},{"key":"10.1016\/j.humpath.2021.07.010_bib2","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/bcr767","article-title":"Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome","volume":"6","author":"Arpino","year":"2004","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.humpath.2021.07.010_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jso.2930480106","article-title":"Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study","volume":"48","author":"Lamovec","year":"1991","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.humpath.2021.07.010_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.2005.03.111","article-title":"Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes","volume":"23","author":"Cristofanilli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2021.07.010_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.semdp.2009.12.009","article-title":"Lobular breast carcinoma and its variants","volume":"27","author":"Rakha","year":"2010","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.humpath.2021.07.010_bib6","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1200\/JCO.2012.46.2440","article-title":"Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial","volume":"31","author":"Metzger-Filho","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2021.07.010_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8","article-title":"Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns","volume":"77","author":"Sastre-Garau","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2021.07.010_bib8","doi-asserted-by":"crossref","first-page":"43265","DOI":"10.1038\/srep43265","article-title":"Molecular classification of lobular carcinoma of the breast","volume":"7","author":"Fu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.humpath.2021.07.010_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2559.2012.04230.x","article-title":"Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type","volume":"61","author":"Monhollen","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2021.07.010_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1053\/ejso.2002.1404","article-title":"Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma","volume":"29","author":"Cocquyt","year":"2003","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.humpath.2021.07.010_bib11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.prp.2016.05.002","article-title":"Lobular breast cancer: clinical, molecular and morphological characteristics","volume":"212","author":"Christgen","year":"2016","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.humpath.2021.07.010_bib12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10549-012-2002-z","article-title":"Invasive lobular breast cancer: subtypes and outcome","volume":"133","author":"Iorfida","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2021.07.010_bib13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and progesterone receptor testing in breast cancer","volume":"144","author":"Allison","year":"2020","journal-title":"Archc Pathol Lab Med"},{"key":"10.1016\/j.humpath.2021.07.010_bib14","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer","volume":"142","author":"Wolff","year":"2018","journal-title":"Archc Pathol Lab Med"},{"key":"10.1016\/j.humpath.2021.07.010_bib15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1309\/4NTU-N6K4-F8JF-EWRX","article-title":"HER2\/neu amplification in breast cancer: stratification by tumor type and grade","volume":"117","author":"Hoff","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2021.07.010_bib16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1309\/YMJ3A83TB39MRUT9","article-title":"Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas","volume":"123","author":"Lal","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2021.07.010_bib17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0960-9776(02)00273-4","article-title":"Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study","volume":"12","author":"Bilous","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.humpath.2021.07.010_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00129039-200203000-00007","article-title":"Comparison of HER-2\/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer","volume":"10","author":"Rosenthal","year":"2002","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2021.07.010_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/modpathol.3800273","article-title":"Invasive lobular carcinoma: to grade or not to grade","volume":"18","author":"Bane","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2021.07.010_bib20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1365-2559.2010.03716.x","article-title":"Suitability of infiltrative lobular breast carcinoma for anti-human epidermal growth factor receptor 2 treatment after the ASCO\/CAP and 2009 St Gallen International Expert Consensus meeting","volume":"57","author":"Vergine","year":"2010","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2021.07.010_bib21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1365-2559.2001.01252.x","article-title":"Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas","volume":"39","author":"Frolik","year":"2001","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2021.07.010_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1309\/AJCP7URIW0QETTAT","article-title":"Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics","volume":"136","author":"Yu","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2021.07.010_bib23","first-page":"109","article-title":"HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer","volume":"4","author":"Zeillinger","year":"1989","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2021.07.010_bib24","first-page":"553","article-title":"Comparison of ER, PR and HER-2\/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer","volume":"9","author":"Azizun","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.humpath.2021.07.010_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/ajcp\/aqz194","article-title":"Frequency, clinicopathologic characteristics, and follow-up of HER2-positive nonpleomorphic invasive lobular carcinoma of the breast","volume":"153","author":"Zhang","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2021.07.010_bib26","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","article-title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"15","author":"Gianni","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2021.07.010_bib27","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2\u2013positive operable breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2021.07.010_bib28","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2021.07.010_bib29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-010-0939-3","article-title":"A multicenter randomized phase II study of sequential epirubicin\/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients","volume":"122","author":"Pierga","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2021.07.010_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2021.07.010_bib31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/1097-0142(19910715)68:2<331::AID-CNCR2820680221>3.0.CO;2-X","article-title":"C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia","volume":"68","author":"Porter","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2021.07.010_bib32","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1007\/s13277-015-3293-6","article-title":"Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population","volume":"36","author":"Wang","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.humpath.2021.07.010_bib33","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.7150\/jca.24701","article-title":"Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: evidence from a meta-analysis of randomized controlled trials","volume":"9","author":"Wu","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.humpath.2021.07.010_bib34","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10549-011-1735-4","article-title":"Invasive lobular carcinoma: response to neoadjuvant letrozole therapy","volume":"130","author":"Dixon","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2021.07.010_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13058-015-0519-x","article-title":"Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics","volume":"17","author":"McCart Reed","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.humpath.2021.07.010_bib36","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/annonc\/mdl114","article-title":"Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution","volume":"17","author":"Tubiana-Hulin","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2021.07.010_bib37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/bjc.2012.557","article-title":"Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas","volume":"108","author":"Delpech","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2021.07.010_bib38","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.amjsurg.2017.11.011","article-title":"Neoadjuvant systemic therapy in invasive lobular breast cancer: is it indicated?","volume":"215","author":"Tsung","year":"2018","journal-title":"Am J Surg"},{"key":"10.1016\/j.humpath.2021.07.010_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-014-2861-6","article-title":"Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma","volume":"144","author":"Loibl","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2021.07.010_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10549-012-2233-z","article-title":"Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer","volume":"136","author":"Lips","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2021.07.010_bib41","first-page":"1","article-title":"\u0394Ki67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment","volume":"42","author":"Lanza","year":"2020","journal-title":"Tumor Biol"},{"key":"10.1016\/j.humpath.2021.07.010_bib42","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/jnci\/djt306","article-title":"An international Ki67 reproducibility study","volume":"105","author":"Polley","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2021.07.010_bib43","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10549-008-9893-8","article-title":"HER2 in well differentiated breast cancer: is testing necessary?","volume":"112","author":"Haines","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2021.07.010_bib44","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1002\/cncr.11828","article-title":"Do we need HER-2\/neu testing for all patients with primary breast carcinoma?","volume":"98","author":"Taucher","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2021.07.010_bib45","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice guideline focused update","volume":"36","author":"Antonio","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817721001313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817721001313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:38:44Z","timestamp":1758645524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817721001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":45,"alternative-id":["S0046817721001313"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2021.07.010","relation":{},"ISSN":["0046-8177"],"issn-type":[{"type":"print","value":"0046-8177"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological features of and neoadjuvant therapy for human epidermal growth factor receptor 2-positive classic invasive lobular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2021.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}